MA42946B1 - Sels et formes solides d'un antibiotique de type monobactame - Google Patents

Sels et formes solides d'un antibiotique de type monobactame

Info

Publication number
MA42946B1
MA42946B1 MA42946A MA42946A MA42946B1 MA 42946 B1 MA42946 B1 MA 42946B1 MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A MA 42946 B1 MA42946 B1 MA 42946B1
Authority
MA
Morocco
Prior art keywords
salts
solid forms
monobactam antibiotic
oxo
amino
Prior art date
Application number
MA42946A
Other languages
English (en)
French (fr)
Other versions
MA42946A (fr
Inventor
Robert Lowell Simmons
Anthony Casarez
Mika Lindvall
Heinz Ernst Moser
Eric Aubin
Andreas Fisch
Michael Mutz
Bernd Ulrich Riebesehl
Marc Schoenhentz
Zaixing Li
Folkert Reck
Vijay Sethuraman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA42946A publication Critical patent/MA42946A/fr
Publication of MA42946B1 publication Critical patent/MA42946B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA42946A 2015-09-23 2016-09-20 Sels et formes solides d'un antibiotique de type monobactame MA42946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23
PCT/CN2016/099482 WO2017050218A1 (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic

Publications (2)

Publication Number Publication Date
MA42946A MA42946A (fr) 2018-08-01
MA42946B1 true MA42946B1 (fr) 2020-10-28

Family

ID=58385723

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42946A MA42946B1 (fr) 2015-09-23 2016-09-20 Sels et formes solides d'un antibiotique de type monobactame

Country Status (26)

Country Link
US (1) US10919887B2 (it)
EP (1) EP3353175B1 (it)
JP (1) JP6837480B2 (it)
KR (1) KR102749337B1 (it)
CN (1) CN108137573B (it)
AU (1) AU2016327264B2 (it)
CA (1) CA2999794C (it)
CL (2) CL2018000745A1 (it)
CY (1) CY1123509T1 (it)
DK (1) DK3353175T3 (it)
EA (2) EA037569B1 (it)
ES (1) ES2817537T3 (it)
HR (1) HRP20201423T1 (it)
HU (1) HUE050849T2 (it)
IL (1) IL258254B (it)
LT (1) LT3353175T (it)
MA (1) MA42946B1 (it)
MX (1) MX377532B (it)
PH (1) PH12018500653B1 (it)
PL (1) PL3353175T3 (it)
PT (1) PT3353175T (it)
RS (1) RS60805B1 (it)
RU (1) RU2754180C2 (it)
SI (1) SI3353175T1 (it)
SM (1) SMT202000480T1 (it)
WO (1) WO2017050218A1 (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019026004A2 (en) * 2017-08-02 2019-02-07 Novartis Ag CHEMICAL PROCESS FOR THE PREPARATION OF ANTIBIOTIC MONOBACTAM AND ITS INTERMEDIATES
CN111032792A (zh) * 2017-08-16 2020-04-17 株式会社Lg化学 包含zif类粉末的白色颜料、聚合物树脂膜和使用白色颜料改变介质的颜色的方法
US20200360349A1 (en) * 2017-11-10 2020-11-19 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
EP3747883A4 (en) * 2018-01-29 2020-12-16 Medshine Discovery Inc. MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION
CN113227088B (zh) * 2018-12-18 2022-05-31 南京明德新药研发有限公司 单环β-内酰胺化合物在制药中的应用
CN114787158B (zh) * 2019-11-22 2023-10-24 苏州二叶制药有限公司 磺酰脲环取代的单环β-内酰胺类抗生素
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
EP4007759A4 (en) 2020-08-06 2024-04-10 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAM COMPOUNDS, THEIR PRODUCTION AND USE AS ANTIBACTERIAL AGENTS
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
KR900005112B1 (ko) 1982-05-31 1990-07-19 반유세이야꾸 가부시끼가이샤 2-옥소-1-아제티딘술폰산 유도체의 제조방법
EP0096297B1 (de) 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd 2−オキソ−1−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
DK2960244T3 (en) 2008-10-31 2016-11-28 Shionogi & Co Cephalosporin antibiotic with catechol
SG171781A1 (en) * 2008-12-19 2011-07-28 Pfizer Monocarbams
CA2815821C (en) * 2010-11-29 2015-07-07 Pfizer Inc. Monobactams useful for treating bacterial infections
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2015103583A1 (en) 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
PL3122745T3 (pl) * 2014-03-24 2019-08-30 Novartis Ag Monobaktamowe związki organiczne do leczenia zakażeń bakteryjnych

Also Published As

Publication number Publication date
CN108137573A (zh) 2018-06-08
EA037569B1 (ru) 2021-04-15
EA202092620A1 (ru) 2021-06-30
EP3353175A1 (en) 2018-08-01
SI3353175T1 (sl) 2020-11-30
CN108137573B (zh) 2021-06-11
MX377532B (es) 2025-03-10
CL2018000745A1 (es) 2018-06-22
CY1123509T1 (el) 2022-03-24
RU2754180C2 (ru) 2021-08-30
KR20180054816A (ko) 2018-05-24
EA201890771A1 (ru) 2018-09-28
JP6837480B2 (ja) 2021-03-03
PL3353175T3 (pl) 2021-02-22
US20180273522A1 (en) 2018-09-27
EP3353175B1 (en) 2020-08-12
ES2817537T3 (es) 2021-04-07
PT3353175T (pt) 2020-09-10
MA42946A (fr) 2018-08-01
HK1257271A1 (en) 2019-10-18
AU2016327264A1 (en) 2018-05-10
HUE050849T2 (hu) 2021-01-28
HRP20201423T1 (hr) 2020-12-11
RU2018114480A3 (it) 2020-06-09
CA2999794C (en) 2023-08-15
AU2016327264B2 (en) 2019-06-27
CA2999794A1 (en) 2017-03-30
JP2018528241A (ja) 2018-09-27
US10919887B2 (en) 2021-02-16
PH12018500653B1 (en) 2022-05-04
DK3353175T3 (da) 2020-09-14
RU2018114480A (ru) 2019-10-23
MX2018003592A (es) 2018-06-18
CL2019003324A1 (es) 2020-04-17
IL258254B (en) 2021-02-28
KR102749337B1 (ko) 2025-01-03
SMT202000480T1 (it) 2020-11-10
EP3353175A4 (en) 2019-06-26
RS60805B1 (sr) 2020-10-30
IL258254A (en) 2018-05-31
BR112018005805A2 (pt) 2018-10-16
PH12018500653A1 (en) 2018-10-01
LT3353175T (lt) 2020-10-12
WO2017050218A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MA42946B1 (fr) Sels et formes solides d'un antibiotique de type monobactame
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
EP2727605A4 (en) A POLYETHYLENE GLYCOL OR A DERIVATIVELY PEGYLATED EXENDIN-4-ANALOGONE, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES THEREFOR AS AN ACTIVE AGENT
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
ES2546847T3 (es) Formulaciones de un inhibidor de la Src/Abl
PE20141148A1 (es) Mesilato de n-[5-(aminosulfonil)-4 metil-1-3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
MX375068B (es) Un grupo de compuestos utilizados para el tratamiento o prevencion de hiperuricemia o gota.
MX374628B (es) Formulacion que comprende un agente hipolipidemico.
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
BR112022006608A2 (pt) Inibidores orais do fator d do complemento
BR112017004796A2 (pt) método para utilizar derivados de ácido hidroxâmico e substância antibacterial em combinação
BR112013020456A2 (pt) nova composição antifúngica
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
HRP20200161T1 (hr) (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja
MX2017010666A (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
AR087346A1 (es) Formulaciones de compuestos de tiofeno
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
AU2018311521A8 (en) Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid